http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114105958-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2021-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114105958-B |
| titleOfInvention | A group of 2-anilinopyrimidine derivatives containing hydroxamic acid and application thereof |
| abstract | The invention belongs to the field of medicinal chemistry, and specifically relates to a class of 4-triazole-2-anilinopyrimidine derivatives, the structure of which is as follows: ; Wherein, R 1 is methyl, ethyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; R 2 is hydrogen, fluorine, trifluoromethyl; X is oxygen or . Pharmacological experiments show that these compounds and their pharmaceutically acceptable salts have the effect of inhibiting tumor cell proliferation. |
| priorityDate | 2021-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 218.